A senolytic ADC drives synthetic lethality and immune surveillance for senescent cancer cell destruction

conatumumab (AMG 655) - Amgen

salinomycin (HSB-1216) - Canton Strategic Holdings

J. Chen 1; Y. Deng 1; G. Casagrande Raffi 2; X. Feng 1; S. Lu 1; H. Xie 1; R. Beijersbergen 2; J. Yang 1; R. Bernards 2; L. Wang 1

Jun 17, 2026